Zoetis Inc. (NYSE:ZTS) Shares Sold by Haverford Trust Co

Haverford Trust Co reduced its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,433 shares of the company's stock after selling 3,777 shares during the period. Haverford Trust Co's holdings in Zoetis were worth $20,600,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Howard Capital Management Group LLC boosted its position in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company's stock worth $20,489,000 after acquiring an additional 883 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Zoetis by 17.3% in the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company's stock worth $464,497,000 after purchasing an additional 351,372 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Zoetis during the 3rd quarter worth approximately $458,000. Pacer Advisors Inc. grew its position in shares of Zoetis by 15.4% in the third quarter. Pacer Advisors Inc. now owns 46,611 shares of the company's stock valued at $9,107,000 after purchasing an additional 6,237 shares in the last quarter. Finally, Nwam LLC increased its holdings in shares of Zoetis by 4.1% in the third quarter. Nwam LLC now owns 4,908 shares of the company's stock valued at $959,000 after purchasing an additional 193 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Remove Ads

Zoetis Trading Down 1.2 %

NYSE:ZTS traded down $1.99 during trading hours on Friday, reaching $163.03. 1,550,283 shares of the stock were exchanged, compared to its average volume of 2,595,079. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The business has a 50-day moving average of $166.40 and a two-hundred day moving average of $174.67. The company has a market capitalization of $73.00 billion, a price-to-earnings ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.23%. Zoetis's dividend payout ratio (DPR) is 36.56%.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent research reports. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective on the stock. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective for the company. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis has an average rating of "Buy" and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.